External Resource
April 30, 2015 - Abusive Litigation Practices of Patent Trolls
COGR and other higher education associations released a statement expressing the view that bipartisan legislation introduced in the Senate, seeking to address abusive litigation practices of patent trolls while protecting the integrity of our patent system, was a substantial improvement over the pending House version (HR 9).
AAU, COGR PRAISE DOD MEMORANDUM, ISSUE REPORT ON RESTRICTIVE CLAUSES IN UNIVERSITY RESEARCH CONTRACTS
The document announces the issuance of a memorandum by Undersecretary of Defense John J. Young, Jr., which affirms the Department of Defense’s policy to avoid restricting publication or dissemination of results from DOD-funded basic and applied research, except in cases where such research is classified or otherwise legally restricted. This policy clarification follows concerns highlighted in a ne
How_to_Conduct_Non-Federal_Stem_Cell_Research_Without_Violating_the_Federal_Stem_Cell_Funding_Prohibition
The article by Robert J. Kenney Jr. provides comprehensive guidance for federally funded research institutions seeking to conduct human embryonic stem cell (hESC) research that is prohibited from federal funding under the Bush administration’s policy. The policy, announced in August 2001, restricts the use of federal funds to a narrow set of pre-approved hESC lines, necessitating stringent safegua
Approaches_to_Developing_an_Institutional_Conflict_of_Interest_Policy_-_Section_Six
Section Six of the COGR document "Approaches to Developing an Institutional Conflict of Interest Policy" provides a curated resource bibliography and comprehensive list of links to institutional and federal policies relevant to the development of conflict of interest (COI) policies at universities and research organizations. The primary focus is on institutional financial conflicts of in
COGR Testimony at NIH Hearings on March-in Rights
NIH has denied the request from Essential Inventions, Inc. to exercise march-in rights under The Bayh-Dole Act in connection with the pricing of Norvir, marketed by Abbott Laboratories for the treatment of patients with HIV/AIDS. The decision and related materials are available online.
